Sort   by:  
 Page size 
UnknownBody Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database.
Not available
S-EPMC5070548 | biostudies-literature
TranscriptomicsChromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent.
Background & Aims: The metastatic process is complex and remains a major obstacle in the management of colorectal cancer (CRC). To gain a better insight into the biologic events driving the metastatic process we investigated genomic aberrations in a large cohort of matched CRC primaries and distant ...
ORGANISM(S): Homo sapiens 
2014-02-10 | E-GEOD-38479 | biostudies-arrayexpress
UnknownPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Not available
S-EPMC4878048 | biostudies-literature
GenomicsDirect Detection of Early-stage Cancers Using Circulating Tumor DNA
Early detection and intervention are likely to be the most effective means for reducing morbidity and mortality of human cancer. However, development of methods for noninvasive detection of early-stage tumors has remained a challenge. We have developed an approach called targeted error correction se...
EGAS00001002577 | EGA
Genomicsena-DATASET-JHU-SOM-01-09-2017-17:11:13:045-143 - samples
The dataset for Direct Detection of Early-Stage Cancers using Circulating Tumor DNA includes 602 bam files from next-generation sequencing on the Illumina HiSeq2500 or MiSeq. The samples analyzed include cancer cell lines as well as plasma and tissue specimens from healthy individuals and patients ...
EGAD00001003601 | EGA
GenomicsDAC for Direct Detection of Early-stage Cancers Using Circulating Tumor DNA
Data Access Committee EGAC00001000701
EGAC00001000701 | EGA
TranscriptomicsBeyond KRAS mutation status: influence of KRAS copy number status and microRNAs on response to cetuximab in metastatic colorectal cancer patients
KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor (EGFR) antibodies in metastatic colorectal cancer (mCRC). Novel predictive markers are required to further improve the selection of patients for this treatment. Here, we assessed the influence of m...
ORGANISM(S): Homo sapiens 
2012-01-01 | E-GEOD-32048 | biostudies-arrayexpress
TranscriptomicsRecurrent breakpoint genes in colorectal cancer
In this study our aim was to document recurrent DNA copy number aberration associated breakpoints in primary tumors of colorectal cancer patients that ultimately received systemic treatment in the context of metastatic disease. Such data can be used to catalogue copy number aberration associated bre...
ORGANISM(S): Homo sapiens 
2014-11-14 | E-GEOD-63216 | biostudies-arrayexpress
TranscriptomicsGenomic landscape of metastatic colorectal cancer
Response to drug therapy in individual colorectal cancer (CRC) patients is associated with tumor biology. Here we describe the genomic landscape of tumor samples of a homogeneous well-annotated series of patients with metastatic CRC of two phase III clinical trials, CAIRO and CAIRO2. DNA copy number...
ORGANISM(S): Homo sapiens 
2014-11-14 | E-GEOD-36864 | biostudies-arrayexpress
Sort   by:  
 Page size